Comparison of Outcomes after Transplantation of G-CSF–Stimulated Bone Marrow Grafts versus Bone Marrow or Peripheral Blood Grafts from HLA-Matched Sibling Donors for Patients with Severe Aplastic Anemia-Reference-Cited by-同舟云学术

Comparison of Outcomes after Transplantation of G-CSF–Stimulated Bone Marrow Grafts versus Bone Marrow or Peripheral Blood Grafts from HLA-Matched Sibling Donors for Patients with Severe Aplastic Anemia

Published:2011-07 Issue:7 Volume:17 Page:1018-1024
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Chu Roland,Brazauskas Ruta,Kan Fangyu,Bashey Asad,Bredeson Christopher,Camitta Bruce,Chiang Kuang-Yueh,Frangoul Haydar,Gale Robert Peter,Gee Adrian,George Biju,Goldman Frederick D.,Gross Thomas G.,Gupta Vikas,Hale Gregory A.,Isola Luis,Ispizua Alvaro Urbano,Lazarus Hillard,Marsh Judith,Russell James,Sabloff Mitchell,Waller Edmund K.,Eapen Mary

Funder

National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases (NIAID)

NHLBI and NCI

Health Resources and Services Administration (HRSA/DHHS)

Office of Naval Research

AABB

Aetna

American Society for Blood and Marrow Transplantation

Amgen, Inc

anonymous donation to the Medical College of Wisconsin

Astellas Pharma US, Inc

Baxter International, Inc

Bayer HealthCare Pharmaceuticals

Be the Match Foundation

Biogen IDEC; BioMarin Pharmaceutical, Inc

Biovitrum AB; Blood Center of Wisconsin

Blue Cross and Blue Shield Association

Bone Marrow Foundation

Buchanan Family Foundation

Canadian Blood and Marrow Transplant Group

CaridianBCT

Celgene Corporation

CellGenix

GmbH

Centers for Disease Control and Prevention

Children’s Leukemia Research Association

ClinImmune Labs

CTI Clinical Trial and Consulting Services

Cubist Pharmaceuticals

Cylex Inc

CytoTherm

DOR BioPharma, Inc

Dynal Biotech, an Invitrogen Company; Eisai, Inc

Enzon Pharmaceuticals, Inc.

European Group for Blood and Marrow Transplantation

Gamida Cell, Ltd.

GE Healthcare

Genentech, Inc.

Genzyme Corporation; Histogenetics, Inc

HKS Medical Information Systems; Hospira, Inc

Infectious Diseases Society of America

Kiadis Pharma; Kirin Brewery Co., Ltd.

The Leukemia & Lymphoma Society; Merck & Company

The Medical College of Wisconsin

MGI Pharma, Inc.

Michigan Community Blood Centers

Millennium Pharmaceuticals, Inc.

Miller Pharmacal Group

Milliman USA, Inc.

Miltenyi Biotec, Inc.

National Marrow Donor Program

Nature Publishing Group

New York Blood Center

Novartis Oncology

Oncology Nursing Society; Osiris Therapeutics, Inc

Otsuka America Pharmaceutical, Inc.

Pall Life Sciences; Pfizer Inc

Saladax Biomedical, Inc.

Schering Corporation

Society for Healthcare Epidemiology of America; Soligenix, Inc.

StemCyte, Inc

StemSoft Software, Inc

Sysmex America, Inc

THERAKOS, Inc

Thermogenesis Corporation

Vidacare Corporation

Vion Pharmaceuticals, Inc.

ViraCor Laboratories; ViroPharma, Inc

Wellpoint, Inc

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference20 articles.

1. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers;Bensinger;N Engl J Med,2001

2. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease;Storek;Blood,1997

3. Long-term follow-up of high-risk allogeneic peripheral-blood stem-cell transplant recipients: graft-versus-host disease and transplant-related mortality;Brown;J Clin Oncol,1999

4. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT);Champlin;Blood,2000

5. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial;Flowers;Blood,2002

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The state of the art in the treatment of severe aplastic anemia: immunotherapy and hematopoietic cell transplantation in children and adults;Frontiers in Immunology;2024-04-05

2. Donor Selection for Adults and Pediatrics;The EBMT Handbook;2024

3. T Cell-Depleted Peripheral Blood versus Unmanipulated Bone Marrow in Matched Sibling Transplantation for Aplastic Anemia;Transplantation and Cellular Therapy;2023-05

4. Outcome of peripheral blood stem cell transplantation from HLA-identical sibling donors for adult patients with aplastic anemia;International Journal of Hematology;2022-11-15

5. Fludarabine/Cyclophosphamide Conditioning Regimen in Aplastic Anemia Patients Receiving Matched-Sibling Donor Transplant Is Non-inferior to ATG/Cyclophosphamide: A Single-Center Experience from Pakistan;Stem Cells International;2022-09-09